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 ABSTRACT 
 
Sertaconazole is an imidazole derivative, which acts as fungistatics, fungicidal, 
antibacterial, anti inflammatory, antitrichomonal, antipruritic. Present study was taken up 
to develop a topical formulation that releases the drug in controlled manner, reduce the 
side effects associated with topical drug delivery and improve product efficiency with aid 
of microsponges. Microsponges loaded with Sertaconazole were prepared by using quasi 
emulsion solvent diffusion with seven different proportions of polymer Eudragit RS100. 
The developed microsponges were analysed for particle size, production yield, 
entrapment efficiency and drug content. Scanning electron microscopic images of 
microsponges revealed that they are spherical in shape and contain pores. In vitro drug 
release results depicted that microsponges with 1:7 drug polymer ratio were more 
efficient to give extended drug release of 92.02% at the end of 24 hrs. Microsponge were 
then incorporated in to 1% carbopol gel and evaluated for pH, viscosity spredability and 
diffusion study. Thus the formulated microsponges based gel of Sertaconazole would be  
a promising alternative to conventional therapy for safer and efficient treatment of 
various skin disorders like Athelete’s foot and Tineapedis. 
Keywords: Microsponges, Sertaconazole, Eudragit RS100, Controlled drug release, 
Drug content. 
Drug delivery is the process of administering a pharmaceutical compound to 
achieve a therapeutic effect in human or animals2. For decades the acute and chronic 
illness are clinically treated through delivery of drug to patients in form of 
pharmaceutical dosage forms, like tablet, capsule, pills, creams, liquids, ointments, 
aerosols, injectables and suppositories, which are referred to as conventional dosage 
form. The Conventional dosage forms have many disadvantages. 
For maintaining effective concentration of drugs in plasma, it is often necessary to 
administer the drug several times. Failure in maintaining the effective concentration can 
cause fluctuation in drug levels in plasma and lead to poor patient compliance. The 
conventional dosage forms delivering the minimal effective concentration of drug at 
required site or organs, sometimes tend to get into general circulation, at higher 
concentration leading to unwanted side effects. Inorder to overcome the drawbacks of the 
conventional dosage form and to improve the safety and efficacy of drugs, several 
attempts have been made for delivering these active moiety in existing desired 
concentration lead to the development of drug delivery system. The drug delivery system 
are the engineered technologies for the targeting/controlling the release of therapeutic 
agents to the desired site. 
Drug delivery system control the rate at which the drugs are released in to the 
desired part of body. The devices used in new drug delivery approach come under two 
main headings “sustained release system and “controlled release system”. Sustained 
release system: These are delivery systems formulated to retard the release of therapeutic 
agent such that, its release of drug into the systemic circulation are delayed and or 
prolonged. The onsets of its pharmacologic action are often delayed, and the duration of 
its therapeutic effect is sustained. 
Controlled release system: The release of therapeutic moiety from controlled drug 
delivery system, proceeds at a control and the rate can be predicted kinetically and also 
reproducible from one unit to another1.The majority of controlled release dosage forms 
are designed for oral administration. Recently the controlled delivery systems are also 
introduced in, 
 Oral Drug Delivery System 
 Mucosal Drug Delivery System 
 Nasal Drug Delivery System 
 Parenteral Drug Delivery System 
 Vaginal Drug Delivery System 
 Intrauterine Drug Delivery System 
 Ocular Drug Delivery System 
 Transdermal Drug Delivery System 
 
Advantages of controlled release preparation3 
 Decreases the incidence and/or intensity of adverse effects and toxicity. 
 Better drug utilization. 
 More uniform drug concentration in blood. 
 Improved patient compliance. 
 Reduced the dosing frequency. 
 More consistent and prolonged therapeutic effect. 
 
Topical delivery 
Topical delivery includes two basic types of product 
 External topical that are spread, sprayed, or otherwise dispersed on to cutaneous 
tissues to cover the affected area. 
 Internal topical that are applied to the mucous membrane orally, vaginally or on 
anorectal tissues for local activity4. 
For the most part topical preparations are used for the localized effects at the site of their 
application by virtue of drug penetration into the underlying of skin or mucous 
membranes. Although some united drug absorption may occur, it is sub therapeutics 
quantities and generally of minor concern3. 
 
Advantages of topical drug delivery system.4, 7 
 Avoidance of first pass metabolism 
 Convenient and easy to apply. 
 Avoidance of the risks and inconveniences of intravenous therapy and of the 
varied conditions of absorption like pH changes, presence of enzymes, gastric 
emptying time. 
 Achievement of efficacy with lower total daily dosage of drug by continues drug 
input. 
 Avoids fluctuation in drug levels, inter- and intrapatient variations. 
 Ability to easy terminate the medications, when needed. 
 A relatively large area of application in comparison with buccal or nasal cavity. 
 Ability to deliver drug more selectively to specific site. 
 Avoidance of gastro intestinal incompatibility. 
 Providing utilization of drug with short biological half life, narrow therapeutic 
window. 
 Improving physiological and pharmacological response. 
 Improve patient compliance 
 Provide suitability for self medication. 
 
Disadvantages of topical drug delivery systems8, 10 
 Skin irritation of contact dermatitis may occur to the drug or excipients. 
 Poor permeability of some drugs through the skin. 
 Possibility of allergic reaction. 
 Can be used only for drugs which require very small plasma concentration for 
action. 
 Enzyme in epidermis may denature the drug. 
 Drugs of large particle size not easy to absorb through the skin 
Classification of topical drug delivery systems11 
Classification based on physical state 
(a) Solid 
 Powder 
 Aerosol 
 Plaster 
(b) Liquid 
 Lotion 
 Liniment 
 Solution 
 Emulsion 
 Suspension 
 Aerosol 
(c) Semi solid 
 Ointment 
 Cream 
 Paste 
 Gel 
 Jelly 
 
Skin characteristics12, 13 
The skin is not only a protective rap for the body, but also busy frontier which 
mediates between the organism and the environment. It not only controls the loss of 
valuable fluid , but also prevents the penetration of noxious foreign materials and 
radiation and cushions against mechanical stock, but also regulates heat loss and 
transduces incoming stimuli. 
The skin is an organ because it consists of tissues, structurally joined together to 
perform specific activities and has a large surface area. Basal surface area of an average 
adult skin is approximately 2,500cm2 and it weight about 4.8kg in men and 3.2kg in 
women. 
The purpose of topical dosage form is to conveniently deliver drugs to localized area of 
the skin. It is necessary to understand the characteristics of skin to develop an ideal 
topical dosage forms. 
Anatomy of skin 
 
Figure: 1 
 
THE SKIN: The site of precutaneous absorption 
 
Anatomy and physiology of skin: Human skin comprises of three distinct but mutually 
dependent tissues14, 17 
a. The stratified, vascular, cellular epidermis, 
b. Underlying dermis of connective tissues and 
c. Hypodermis. 
 
 
The Epidermis 
The multilayered epidermis varies in thickness,depending on cell size and number 
of cell layers of epidermis, ranging from 0.8 mm on palms and soles down to 0.06 mm on 
the eyelids. Epidermis consists outer stratum corneum and viable epidermis. 
 
Stratum corneum 
This is the outermost layer of skin also called as horney. It is approximately 
10mm thick when dry but swells to several times this thickness when fully hydrated. 
Stratum corneum contains 10 to 25 layers of dead, keratinized cells called corneocytes. 
The layer are flexible but relatively impermeable. The stratum corneum is the principal 
barrier for penetration of drug. The architecture of horney layer may be modeled as a 
wall-like structure. In this model, the keratinized cells function as protein “bricks” 
embedded in lipid “mortar.” The lipids are arranged in multiple bilayers. There is 
sufficient amphiphilic material in the lipid fraction, such as polar free fatty acids and 
cholesterol, to maintain a bilayer form. 
 
Viable epidermis 
The viable epidermis is situated beneath the stratum corneum and varies in 
thickness from 0.06mm on the eyelids to 0.8mm on the palms. As one go deeper, consists 
of various layers as stratum lucidum, stratum granulosum, stratum spinosum and the 
stratum basal. In the basal layer, mitosis of the cells constantly renews the epidermis and 
this proliferation compensates the loss of dead horney cells from the skin surface. As the 
cells produced by the basal layer move outward, they get altered morphologically and 
histochemically, undergoing keratinization to form the outermost layer of stratum 
corneum. 
 
Dermis 
Dermis is 3 to 5mm thick layer and is composed of a matrix of connective tissue, 
which contains blood vessels, lymph vessels and nerves. The cutaneous blood supply has 
essential function in regulation of body temperature. The layer also provides nutrients  
and oxygen to the skin while removing toxins and waste products. Capillaries reach to 
within 0.2 mm of skin surface and provide sink conditions for most molecules penetrating 
the skin barrier. The blood supply thus keeps the dermal concentration of a permeant very 
low and the resulting concentration difference across the epidermis provides the essential 
concentration gradient for transdermal permeation. 
Hypodermis 
The hypodermis or subcutaneous fat tissue supports the dermis and epidermis. It 
serves as a fat storage area. This layer helps to regulate temperature, provides nutritional 
support and mechanical protection. It carries principal blood vessels and nerves to skin 
and may contain sensory pressure organs. For transdermal drug delivery, drug has to 
penetrate through all these three layers and reach into systemic circulation while in case 
of topical drug delivery only penetration through stratum corneum is essential and then 
retention of drug in skin layers is desired. 
MECHANISM OF PRECUTANOUS ABSORPTION 
 
 
Figure: 2 Mechanism of precutanous absorption 
There are three pathways (Figure 2) which can be involved in the transdermal permeation 
of 
chemicals: 
1. Through the intercellular lipid domains in SC 
2. Through the skin appendages; and 
3. Through the keratin bundles in SC. 
Figure: 3 Pathway of transdermal permeation 
There are three possible ways that drug molecules can pass through stratum corneum. 
1. Transfollicular route 
2. Transcellular route 
3. Intercellular route 
 
 
The drug can be absorbed by various pathways through the skin depending on the 
physicochemical properties of the drug. Both lipophilic and hydrophilic drugs are 
absorbed from different routes.18, 19 
 
Transfollicular route; Transfollicular route is the shortest pathway that drug has to pass 
and reach the systemic circulation. This route provides a large area for drug diffusion. 
Skin has various sweat glands, oil glands, hair follicles and pores opening to the outer 
surface of the skin via their ducts. These ducts offer a continuous channel across the 
stratum corneum for drug transport. The factors that affect the drug transport are 
secretion from glands, content and amount of secretion etc. However this route occupies 
only 0.1% of total skin surface and therefore contributes a little.20, 21 
 
Transcellular route; The transcellular route is suitable for hydrophilic drugs. The drug 
passes through the corneocytes of stratum corneum. The highly hydrated keratin provide 
aqueous pathway to the hydrophilic drugs. A number of partitioning and diffusion steps 
are needed to pass the drug through the cell matrix.21, 22 
 
Intercellular route: As the name indicates the intercellular route the drug diffuses 
through the lipid bilayer between the cells. In this route, the molecule stays in the lipid 
bilayer and winds around the keratinocytes on its way to the dermis. Although both paths 
are possible, the most common route of drug penetration is the intercellular route because 
most drug molecules are more soluble in the lipid environment of the bilayer than in the 
protein environment of the keratinocytes.22, 23 
Microsponge: An approach for topical delivery 
Over the past 40 years, the ability to control the delivery rate of active agents to a 
predetermined site in the human body has been one of the biggest challenges till date met 
by continued innovative solutions by the medical profession and drug industry. Because 
of this some areas of pharmaceutical research have been focused on the controlled 
delivery of systemic drugs.24 
Various predictable and reliable systems have been developed for systemic drugs 
under the title of trasdermal delivery systems using the skin as portal entry. Transdermal 
patches developed in 1970’s improved the delivery of drugs such as nitro glycerine and 
scopolamine resulting in better control of therapeutic dose, simpler dosage regimens, and 
fewer side effects than the more traditional oral or parentral administration of the same 
drug. And more over these devices mimicked the intravenous administration of the drug 
which is not patient compliance.25 In general, these delivery systems have improved the 
efficiency and safety of various drugs. Controlled release of drugs on to the epidermis 
assure that the drug remains primarily localized and does not enter the systemic 
circulation in significant amount thereby minimizing the side effects. 
Although transdermal delivery systems can be efficient in supplying drugs for 
systemic effects they are not practical for controlling the delivery of materials whose 
final target is the skin itself.26 
No efficient vehicle have been developed for the controlled and localized delivery 
of drugs in to the stratum corneum and underlying skin layers. 
Yet there are many instance when epidermal localization of a drug is desirable, 
but absorption beyond the epidermis undesirable.27 
Corticosteroids are the suitable examples for these problems. Although 
corticosteroids are effective for skin disorders, their topical application results in 
significant systemic absorption; this may leads to unwanted side effects such as adrenal 
suppression or interference with immune functions. 
The same is true in case of cosmetics like sunscreens, winter cares and drugs for 
the treatment of epidermal infection and allergies like acne, eczema, hyper pigmentation 
etc. it is necessary to maximize/lengthen the time of residence of these active ingredient 
on the skin surfaces or within the outer layers of the epidermis while minimizing its 
trasepidermal penetration into the body28. 
Another problem with the application of topical drug is the most of the vehicles, 
such as ointment, often prove aesthetically unappealing; greasiness stickiness or even 
discoloration in clothing can make daily ware unpleasant.29 
This frequently results in patient incompliance, many of these conventional 
vehicles require high concentration of active ingredients for effective therapy because of 
their low efficiency as a delivery system. As a result, irritation or allergic response can be 
elicited in a significant percentage of users. 
Other disadvantages of conventional topical delivery system are the uncontrolled 
evaporation of active ingredient, unpleasant odour, and the potential incompatibility of 
one or more drugs with each other or with the vehicle.30 
Moreover conventional formulations of topical drugs are intended to work on the 
outer layers of the skin. Typically such products release their active ingredients upon 
application, producing a highly concentrated layer of active ingredients that is rapidly 
absorbed. This causes systemic side effects.29 
Thus, there is a need to develop a delivery system to maximize residence time of 
the active pharmaceutical ingredient (API) in the skin. Such a new system would possibly 
increase the efficacy of the topically active agents while enhancing product safety. The 
microsponges are polymeric delivery devices which contain active ingredients with 
release API onto the skin over of time in response to a trigger. 
 
MICROSPONGE TECHNOLOGY27 
Microsponges are patented polymeric delivery systems consisting of porous 
microspheres that can entrap a wide range of active ingredients such as emollients, 
fragrances, essential oils, sunscreens, and anti-infective, anti-fungal, and anti- 
inflammatory agents30. Like a true sponge, each microsphere consists of a myriad of 
interconnecting voids within a non-collapsible structure, with a large porous surface. The 
microsponge technology was developed by Won in 1987, and the original patents were 
assigned to Advanced Polymer Systems, This company developed a large number of 
variations of the technique and applied those to the cosmetic as well as over-the-counter 
(OTC) and prescription pharmaceutical products. 
Structure of microsponges 
 
The size of the microsponges can be varied, usually from 5 – 300 μm in diameter, 
depending upon the degree of smoothness or after-feel required for the end formula. 
Although the microsponge size may vary, a typical 25 μm31 sphere can have up to 
250000 pores and an internal pore structure equivalent to 10 ft in length, providing a total 
pore volume of about 1 ml/g. This results in a large reservoir within each microsponge, 
which can be loaded with up to its own weight of active agent. The microsponge particles 
themselves are too large to be absorbed into the skin and this adds a measure of safety to 
these microsponge materials. Another safety concern is the potential bacterial 
contamination of the materials entrapped in the microsponge. As the size of the pore 
diameter is smaller, the bacteria ranging from 0.007 to 0.2 μm cannot penetrate into the 
tunnel structure of the microsponges. 
Reslease of active ingredients from conventional topical formulation over an 
extended period of time is quite difficult. These vehicles high concentration of active 
agents for effective therapy because of their low efficacy of delivery system, resulting in 
to irritation and allergic reaction in significant users. In contrast, microsponge technology 
allow an even and sustained rate of release, reducing irritation while maintaining 
efficacy. Their high degree of cross linking result in particles that are insoluble, inert of 
sufficient strength to stand up to the high shear commonly used in manufacturing of 
creams, lotion, and powder.31 
Their characteristic feature is the capacity to adsorb or ” load” a high degree of 
active materials into the particles and on its surface. Its large capacity for entrapment of 
actives, up to three times its weight, differentiate microsponge products from other types 
of dermatological delivered system. 
Figure: 4 View of Microsponges 
 
 
Characteristics of microsponges 32, 33 
 
 MDS have stable over ranges of pH 1 to 11 
 They are stable at temperature 130° C 
 They are compatible with most vehicles and ingredients 
 Free flowing and cost effective 
 They have higher pay load is up to 50 – 60% 
 Microsponge formulations are self sterilizing as their average pore size is 0.25um 
where bacreia cannot penetrate. 
Advantages of MDS 34, 35 
 
 Microsponges are microscopic sphere capable of absorbing skin secretions, 
therefor reducing oiliness and shine from the skin(absorb oil up to 6 times its 
weight without drying) 
Eg :- oil free matte block spf20 
 It provide continuous action up to 12 hrs i.e. extended release36,37,38 
Eg :- Epi Quin Micro 
The  microsponge system uses microscopic reservoirs that entrap 
Hydroquinone and retinol. 
The MDS release these ingredients into the skin gradually throughout the 
day.Improve thermal, chemical, and physical stability. 
 These are non-irritating, non mutagenic, non allergic and non toxic. 
Eg :- carac cream, 0.5% 
Advantages over conventional formulation 
 
Conventional formulations of topical drugs are intended to work on the outer 
layers of the skin. Such products release their active ingredients upon application, 
producing a highly concentrated layer of active ingredient that is rapidly absorbed.39 
When compare to the Microsponge system can prevent excessive accumulation of 
ingredients within the epidermis and the dermis. Potentially, the Microsponge system can 
reduce significantly the irritation of effective drugs without reducing their efficacy. For 
example, by delivering the active ingredient gradually to the skin like MDS-Benzoyl 
peroxide formulation have excellent efficacy with minimal irritation40. 
Advantages over microencapsulation and liposomes41 
 
The MDS has advantages over other technologies like microencapsulation and 
liposome. Microcapsule cannot usually control the release rate of actives. Once the wall 
is ruptured the active contained within microcapsules will be released. Liposome does 
suffer from lower paylod, difficult formulation, limited chemical stability and microbial 
instability. While microsponge system in contrast to the above system are stable over 
range of pH 1 to 11, temperature up to 1300 C compatible with most vehicle and 
ingredients, self sterilizing as average pore size is 0.25um where bacteria cannot 
penetrate higher paylod (50-60%) still free flowing and can be cost effective.42 
Advantages over ointments 
 
Ointments are often aesthetically unappealing, greasiness, stickiness etc. that 
often results into lack of patient compliance43. These vehicles require high concentrations 
of active agents for effective therapy because of their low efficiency of delivery system, 
resulting into irritation and allergic reactions in significant users. Other drawbacks of 
topical formulations are uncontrolled evaporation of active ingredient, unpleasant odour 
and potential incompatibility of drugs with the vehicles, when microsponge system 
maximize amount of time that an active ingredient is present either on skin surface or 
within the epidermis, while minimizing its transdermal penetration into the body 44 . 
Characteristic of actives that is entrapped into microsponges 
 
 It shoulbe either miscible in monomer45 as well as capable of being made 
miscible by addition of small amount of a water immicible solvent. 
 It should be inert to monomers and should not increase the viscosity of the 
mixture during formulation. 
 It should be water immiscible or nearly only slightly soluble. 
 It should not collapse spherical structure of the microsponge. 
 It should be stable in contact with polymerization46 catalyst and also in 
conditions of polymerization. 
 Not more than 10 to 12%wlw microsponges must be incorporated in to the 
vehicle in order to avoid cosmetic problems. 
 Paylod and polymer design of the microsponges for active must be 
optimized for required release rate for given period of time. 
Polymers used in Microsponge preparation 
 
There are various polymer, which are used in preparation of microsponges. 
Usually monomers like styrene, Di vinyl benzene, Ethyl vinyl benzene and methyl 
methacrylate are employed in liquid -liquid suspension polymerization technique. Where 
Eudragit RS100 and carbopol were employed for quasi emulsification technique.  None 
of the above mentioned polymer were found to be superior to others when properties 
were compared. Eudragit polymers are copolymers derived from esters of acrylic and 
methacrylic acid, whose physicochemical properties are determined by functional groups. 
Eudragit polymer are available in a wide range of different physical forms. Eudragit 
RS100 is employed for quasi emulsification technique. 
Method of preparation of microsponges47,48,49 
 
Based on the physio chemical properties of the drug to be incorporated in 
microsponge, this is divided in to two ways, 
1. One step process or liquid liquid suspension polymerization 
2. Two step process or quasi- emulsion diffusion 
 
Liquid liquid suspension polymerization 
 
In this method the monomers are firstly dissolved along with active ingredients in 
a suitable solvent solution of monomer and are then dispersed in the aqueous phase with 
agitation. Aqueous phase typically consists of addictives such as surfactants and 
dispersants (suspending agent) etc inorder to facilitate the formation of suspension. Once 
the suspension is established with distinct droplets of the preferred size then 
polymerization is initiated by the addition of catalyst or by increasing temperature as well 
as irradiation.50 The polymerization method leads to the development of a reservoir type 
of system that opens at the surface through pores. During the polymerization, an inert 
liquid immiscible with water however completely miscible with monomer is used to form 
the pore network in some case. Once the polymerization process is complete the liquid is 
removed leaving the microsponges which is permeate within preformed microsponges 
then, incorporated the variety of active substances like antifungal, anti acne, anti 
inflammatory etc and act as a topical carriers.14 
 
 
Figure: 5 Liquid liquid suspension polymerization 
 
 
The various steps53 involved in the preparation of microsponges are summarized 
as follows 
Step1: Selection of monomers and combination of monomers 
Step2: Formation of chain monomers as polymerization starts 
Step3: Formation of ladders as a result of cross-linking between chain monomers. 
Step4: Folding of monomer ladder to form spherical particles. 
Step5: Agglomeration of microsphere leads to the production of bunches of 
microspheres 
Step6. Binding of bunches to produce microsponges. 
 
 
 
Quasi –emulsion solvent diffusion54 
 
Microsponges were prepared by quasi emulsion solvent diffusion technique. In 
this method external phase and internal phase were used. The internal phase is organic 
phase containing drug, ethyl alcohol/ acetone (good solvent), polymer and 
Triethylcithrate(TEC)/ trichloro-methane /Dichloromethane (bridging liquid), which was 
added at an amount of 20% of the polymer in order to facilitate the plasticity. The 
external phase mostly consists of distilled water and polyvinyl alcohol (PVA). 
Weighed amount of drug and polymer were dissolved in measured quantity of 
ethanol. The formed ethanolic solution was poured into water containing polyvinyl 
alcohol. The system was thermally controlled at 20°C Ethanol solution was finely 
dispersed in the aqueous phase as discrete droplet of the polymer solution of the drug 
were solidified in the aqueous phase via counter diffusion of ethanol and water out the 
droplets. The formed micro particle were filtered and washed with distilled water before 
being tray dried at room temperature. 
Steps 
 
This is a two step process where the microsponges can be prepared by quasi- 
emulsion solvent diffusion method using the different polymer amount 
Figure: 6 Quasi –emulsion solvent diffusion 
 
 To prepare the inner phase, Eudargit RS 100 is dissolved in ethyl alcohol. 
 
 Then drug can be added to solution and dissolved under ultrasonication at 35°C 
 
 The inner phase is then poured into PVA solution in water (outer phase) 
 
 Following 60 min of stirring, the mixture is filtered to separate the microsponges. 
 
 The microsponges are in air-heated oven at 400C for 12 hr and weighed to 
determine production yield (PY) 
Drug release mechanism55 
 
Microsponges can be intenteded to release given amount of active ingredients 
over time in response to one or more following external triggers i.e. pressure, pH, 
temperature change and solubility etc which are described as follows . 
Temperature changed56 :- entrapped materials, such as sunscreens and emollient can be 
too viscous at room temperature to flow spontaneously from the microsponge onto the 
skin, when warmed by the skin temperature, the sun and the other heat source , their 
viscosity may decrease, resulting in an increase flow rate. 
pH 57 : The pH responsive MDS involves coating of conventional microsponge delivery 
system with enteric coating type of material, which imparts pH responsiveness to this 
system. 
Pressure58:- rubbing or pressure applied can release the active ingredients from 
microsponges on to skin. 
Solubility59 :- microsponges loaded with water miscible ingredients like antiseptics and 
anti-perspirants will release the ingredient in the presence of water. The release can also 
be activated by diffusion but taking into consideration, the partition coefficient of the 
ingredient between the microsponges and the external system. 
Effect of formulation variables on physical properties of microsponges 
 
a) Effect of composition of internal and external phase 
It is formed that particle size of microsponges were directly propotional to the 
apparent viscosity of dispersed phase. Larger the difference between apparent 
viscosity of dispersed and contineous phase (external phase), due to the higher 
viscosity of the internal phase, the globules of the formed emulsion can hardly be 
divided in to smaller particles and bigger droplets are found resulting in a increase 
in mean particle size. 
Good microsponges can be produce only when 3 to 5ml of internal phase is used 
.when the amount of internal phase is increased from 5 to 15ml , the production 
yield and drug content of microsponge is found to be decreased this is due to the 
lower concentration of the drug in the higher volume of internal phase. 
 
b) Effect of drug to polymer ratio 
When the amount of polymer is kept constant but the ratio of drug to polymer is 
varied , the drug containing capacity is not much effected by drug to polymer 
ratio but the production yield can be enormously changed from minimum ratio to 
maximum one. Another parameters which is effected from the drug polymer ratio 
change is particle size. It has been observed that the drug amount is increased 
particle size of the microsponges is also increased. 
 
 
Effect of process variables on physical properties of microsponges. 
 
 Effect of stirring rate 
As the stirring rate is increased microsponge of smaller size are obtained. 
Increase the stirring rate decrease the production yield but the drug content 
get increased s the stirring rate is increased. This is due to the turbulence 
created within the external phase due to which polymer gets adhered to the 
paddle and production yield gets decreased. 
Benefits60 
 
The microsponge delivery system offers the following benefits: 
 
 Liquid can be converted to powders. 
 Allows for novel product forms advanced oil control – absorbs up to 6 times its 
weight without drying. 
 Extended release – continuous up to 12 hours. 
 Reduced irritation – better tolerance means broader consumer acceptance. 
 Improved product aesthetics – gives product an elegant feel. 
 
 
Flexibility Benefits 
 
 Improve stability – thermal, physical, chemical. 
 Allows incorporation of the immiscible. 
 Improves material processing. 
Application of microsponge system61 
 
Microsponges are porous polymeric microspheres that are used mostly for topical 
and recently for oral administration. It offers the formulator arrange of alternative to 
develop drug and cosmetic products. Microsponges are design to deliver a 
pharmaceutical active ingredient efficiently at the minimum dose and also to enhance 
stability, reduce side effects and modify drug release. 
 
 
Table: 1 
 
Active agents Application 
Anti inflammatory. Eg ;- hydrocortisone Long lasting activity with lessening of skin 
allergic response and dermatoses 
Sunscreen Long lasting product efficacy with 
improved protection against sunburns and 
sun related injuries even ateleved 
concentration and with reduced irritancy 
and sensitization. 
Anti acne, eg ;- benzoyl peroxide Maintained efficacy with decreased skin 
irritation and sensitization 
Anti fungal Sustained release of activities 
Anti dandruff. 
zinc pyrithion 
Eg ;- selenium sulphide, Reduced unpleasant odour with extended 
safty and efficacy. 
Anti pruritis Extended and improved activity 
Skin depigmenting 
hydroquinone 
agent eg ;- Improved stabilization against oxidation 
with improved efficacy and aesthetic 
appeal. 
Rubefacients Prolonged activity with reduced irritancy 
greasiness and odour 
Marketed formulation62, 63 
 
Table 2 
 
Product Advantage Manufacture 
 
Retin –A- Micro 
0.1% and 0.04% tretinoin 
entrapped in MDS for topical 
treatment of acne vulgaris. This 
formulation uses patented methyl 
methacrylate/ glycol 
dimethacrylate cross-polymer 
porous microspheres to enable 
inclusion of the active ingredient, 
tretinoin, in an aqueous gel. 
Ortho-McNeil Pharmaceutical 
Inc 
Carac cream Carac Cream contains 0.5% 
fluorouracil, with 0.35% being 
incorporated into a patented porous 
microsphere (Microsponge) 
composed of methyl methacrylate / 
glycol dimethacrylate cross- 
polymer and dimethicone. Carac is 
a once-a-day topical prescription 
product for the treatment of actinic 
keratosis (AK), a common pre- 
cancerous skin condition caused by 
over-exposure to the sun 
Dermik Laboratories, Inc. 
Berwyn , PA 
Line eliminator 
dual facial 
treatment. 
Lightweight cream with a retinol 
(Vitamin A) in MDS, dual-system 
delivers both immediate and time 
released wrinkle-fighting action. 
Visibly diminishes appearance of 
fine lines, wrinkles & skin 
Avon 
 discolorations associated with 
aging. 
 
Retinol cream, 
retinol 15 night 
cream 
A night time treatment cream with 
Microsponge technology using a 
stabilized formula of pure retinol, 
Vitamin A. Continued use of 
Retinol 15 will result in the visible 
diminishment of fine lines and 
wrinkles, a noticeable 
improvement in the skin 
discolorations due to aging, and 
enhanced skin smoothness 
Biomedic, 
Sothys 
Epi Quin Micro The Microsponge® system uses 
microscopic reservoirs that entrap 
hydroquinone and retinol. The 
microsponges release these 
ingredients into the skin gradually 
throughout the day. This provides 
the skin with continuous exposure 
to hydroquinone and retinol over 
time, which may minimize skin 
irritation. EpiQuin Micro is a 
prescription moisturizing fading 
cream that reduces the impact of 
these conditions known as 
melasma, post inflammatory hyper 
pigmentation or solar lentigines. 
Also help in Age spots, Sun spot 
facial discoloration. 
Skin medica Inc 
Sports cream RS 
and XS 
Topical analgesic-anti- 
inflammatory and counterirritant 
actives in a Microsponge® 
Delivery System (MDS) for the 
management of muculoskeletal 
condition 
Embil Pharmaceutical Co. Ltd 
Salicylic peel 20 
and 30 
Deep BHA peeling agent for 
(professional use only): Salicylic 
acid 20%, Microsponge 
Technology, Excellent exfoliation 
and stimulation of the skin for 
more resistant skin types or for 
faster results. Will dramatically 
improve fine lines, pigmentation, 
and acne concerns. Salicylic Acid 
moves easily through the pores, 
clearing them out while reducing 
inflammation. This treatment 
effectively combats acne, leaving a 
wonderfully smooth and clear 
complexion. 
Biophora 
Micropeel plus/ 
acne peel 
The MicroPeel Plus procedure 
stimulates cell turnover through the 
application of salicylic acid in the 
form of microcrystals using 
Microsponge ® technology. These 
microcrystals target the exact areas 
on the skin that need improvement. 
The Micro Peel Plus aggressively 
out performs other superficial 
chemical peels by freeing the skin 
Biomedic 
 of all dead cells while doing no 
damage to the skin. 
 
Oil free matte 
block spf20 
This invisible oil-free sunscreen 
shields the skin from damaging UV 
sun rays while controlling oil 
production, giving you a healthy 
matte finish. Formulated with 
microsponge technology, Oil Free 
Matte Block absorbs oil, 
preventing shine without any 
powdery residue. 
Dermalogica 
Oil control lation A feature-light lotion with 
technically advanced microsponges 
that absorb oil on the skin's surface 
during the day, for a matte finish. 
Eliminate shine for hours with this 
feature-weight lotion, formulated 
with oil-absorbing Microsponge 
technology. The naturally- 
antibiotic Skin Response Complex 
soothes inflammation and tightness 
to promote healing. Acne-Prone, 
oily skin conditions. 
Fountain cosmetics 
Lactrex TM 12% 
moisturizing 
cream. 
Lactrex™ 12% Moisturizing 
Cream contains 12% lactic acid as 
the neutral ammonium salt, 
ammonium lactate. Microsponge® 
technology has been included for 
comfortable application and long 
lasting moisturization. Lactrex™ 
also contains water and glycerin, a 
SDR Pharmaceuticals, Inc., 
Andover , NJ , U.S.A. 07821 
 natural humectant, to soften and 
help moisturize dry, flaky, cracked 
skin 
 
Dermatologica oil 
control lotion 
A feather-light lotion containing 
microsponges to absorb oil on the 
skin’s surface, helping to combat 
shine and maintain an all-day matte 
finish. Niacinamide, Zinc 
Gluconate, Yeast Extract, Caffeine 
and Biotin purify and inhibit 
overactive sebaceous gland activity 
while soothing irritation. Salicylic 
Acid clears congested follicles to 
minimize future breakout activity, 
while Enantia Chlorantha Bark 
Extract controls over-active oil 
glands, helping to reduce oil. 
John and Ginger Dermalogica 
Skin Care Products 
Aramis fragrances 24 Hour High Performance 
Antiperspirant Spray Sustained 
release of fragrance in the 
microsponge. The microsponge 
comes in the form of an ultra light 
powder, and because it is micro in 
size, it can absorb fragrance oil 
easily while maintaining a free- 
flowing powder characteristic 
where release is controlled due to 
moisture and temperature. 
Aramis Inc. 
Ultra guard Microsponge system that contains 
dimethicone to help protect a 
baby's skin from diaper rash. The 
Scott paper company. 
new wipe contains a skin 
protectant that helps keep wetness 
and irritants from the baby's skin. 
The solution is alcohol-free, 
hypoallergenic and contains 
dimethicone, an ingredient found 
in baby creams, lotions and skin 
protectance 
 
2. AIM AND OBJECTIVE 
 
The proposed work involves formulation and evaluation of sertaconazole 
microsponges by using Eudragit RS100 as polymer. And finally the optimized 
microsponges formulation are incorporated into gel to apply on skin for the treatment of 
fungal infection with sustained release rate and better patient compliance. 
 
The important objectives of the proposed research work are:- 
 
 
 To study the effect of different ratio of drug:polymer on the change in physical 
and morphological properties, particle size and size distribution, encapsulation 
efficiency. 
 To analyze the integrity of the drug in the microsponges by FTIR 
 To incorporate optimized Microsponge formulations in gel formulation. 
 To perform in-vitro drug release studies from the entire drug: polymer ratios. 
 To perform the in-vitro drug diffusion studies of gel formulation 
3. PLAN OF THE WORK 
 
PREFORMULATION STUDIES 
 Determination of Melting Point. 
 Determination of Wavelength. 
 Determination of Solubility. 
 Determination of pH. 
 
 
PREPARATION OF MICROSPONGES OF SERTACONAZOLE 
 Preparation of Microsponge. 
 Incorparation Of Sertaconazole Loded Microsponges In To Gel 
Formulation. 
 
EVALUATION OF MICROSPONGES OF SERTACONAZOLE 
 Drug Excipient Compatibility Studies. 
 Determination Percentage Yield. 
 Drug Loading And Drug Entrapment 
 Particle Size Analysis. 
 Morphology Study Using Scanning Electrone Microscope. 
 In Vitro Dissolution Studies 
 
 
EVALUATION OF SERTACONAZOLE MICROSPONGE GEL 
 Visual Inspection. 
 pH Measurement. 
 Spreadability Studies. 
 Viscosity Measurement. 
 In Vitro Drug Release. 
4. REVIEW LITERATURE 
 
 
 Kawashima et al., (1989)64 have prepared controlled release microsphere of 
Ibuprofen with acrylic polymers by a novel Quasi-Emulsion Solvent-Diffusion 
technique and the microspheres obtained had a matrix or sponge like texture and 
the drug release from the microspheres could be controlled by the type and 
concentration of the polymer. 
 
 Perumal D (2001)65 has worked on the microencapsulation of ibuprofen. The 
microsphere were prepared by the emulsion solvent diffusion technique using 
Eudragit RS 100 as the retardant material. The influence of various process and 
variables like the presence/absence of baffles in the reaction vessel, agitation rate 
and drying time of microsphere, polymer and drug content on the 
microencapsulation efficiency, in vitro drug release and micrometric properties 
were analyzed. By increasing the agitation speed the particle size decreased. By 
drying the microsphere at 40+ 0.50C for 24hrs gave particles with less moisture 
content and free flowing nature. The release studies show that microencapsulation 
with Eudragit RS 100 gave controlled release of the drug. And 9.1% Eudragit RS 
100 released the drug more rapidly, while those with 33.3% Eudragit RS 100 
exhibited slower drug release profile. 
 
 Gonul N et al.,(2003)66 have worked on the effect of pressure and direct 
compression on tableting of microsponges. In this study ketoprofen was used as a 
model drug for systematic delivery. The ketoprofen microsponges were prepared 
by quasi emulsion solvent diffusion technique using Eudragit RS 100 as the 
polymer. The microsponges possess a unique compression property due to their 
matrix or sponge like structure which differed from conventional microcapsules 
or physical mixture. The in vitro release rate studies show that the tablets prepared 
with microsponges exhibited typical drug release profile characterized by 
Higuchi-matrix model. By applying pressure more than 3800 kg/cm2 the drug 
release was higher compared to the lower pressure which was because of the 
structural deformation of microsponges. 
 
 Mandal T K et al., (2001)67 have developed a method for the preparation of 
porous biodegradable controlled release formulation of poly (lactide/glycolide) 
(PLGA) containing pentamidine. Scanning electron microscopy pictures showed 
that these micro particles are highly porous and spherical in shape. Irrespective of 
the oil (corn or mineral) used in the preparation; the micro particles were all 
smaller tan 90nm. A change in the drug/polymer ratio did not change the particle 
size. The efficiency of the encapsulation was higher than 58%. In the presence of 
the corn oil, the efficiency of encapsulation was between 60 and 66%, where as in 
the presence of mineral oil, the efficiency of encapsulation was between 58 and 
74%. The rate of drug release from these micro particles were very high. This 
significantly high rate of drug release from the PLGA micro particles was due to 
the porous surface of morphology. 
 
 Beruto T D et al., (2002)68 have worked on the effect of water in inorganic 
microsponges of calcium phosphates on the porosity and permeability of 
composites made with polymethylmethacrylate. The inorganic powder was placed 
inside the polymeric matrix by polymerization technique in the aqueous mixture 
of the required powders. The polymeric matrix obtained was porous and act as 
local microsponges. The total open porosity was a function of the amount of water 
present, which vaporized after polymerization, leaving behind the empty spaces in 
the polymeric matrix. A linear relationship exists between the composites and the 
amount of water inside the inorganic agglomerates. 
 
 Comoglu T et al., (2003)69 have prepared microsponges containing ketoprofen 
and Eudragit RS 100 by quasi emulsion solvent diffusion method. The effect of 
different mixing speeds, drug/polymer ratios, solvent/polymer ratios on the 
physical characteristics of microsponges as well as the in vitro release rate of the 
drug from the microsponges were investigated. All the factors studies had an 
influence on the physical characteristics of the microsponges. 
 
 
 Baykar T et al., (2003)70 have worked on the effect of the drug/polymer ratio on 
the properties of the verapamil HCL loaded microspheres. The microspheres were 
prepared by solvent evaporation technique using the Eudragit RS 100 as polymer. 
The results show that the drug release profile could be slowed down by increasing 
polymer amount in the formulations and the particle size, surface characteristics 
of microspheres and dissolution of drug could be modified through the variation 
of drug/polymer. 
 
 Sato Y et al., (2004)71 have prepared hollow microsphere by emulsion solvent 
diffusion method utilizing enteric acrylic polymers co-dissolved with drug in a 
mixture of dichloromethane and ethanol. The in vitro release studies of five 
different drugs which differ I aqueous solubility’s were done. The results show 
that the aspirin, salicylic acid and ethoxybenzamide followed higuchi equation 
whereas indomethacin and riboflavin release profiles does not follow the higuchi 
equation. It was because of increased amount of riboflavin loading than the 
solubility of it in the mixture dichloromethane and ethanol. The drug release 
profile show a initial burst release as the insoluble riboflavin crystals were 
released preferentially at the initial stages of the release studies. 
 
 Dortunc et al., (2004)72 have worked on the preparation and in vitro evaluation of 
Eudragit (RS RL) microsphere containing acetazolamide. Microsphere were 
prepared by solvent evaporation technique using acetone/liquid paraffin system. 
The influence of formulation factors (stirring speed, polymer/drug ratio, type of 
polymer, ratio of combination of polymer) on particle size, encapsulation 
efficiency and in vitro characteristics of the microspheres were  investigated. 
Mean particle size changed by changing the polymer/drug ratio or the stirring 
speed of the system. Although the acetazolamide release rate from Eudragit RS 
microspheres were very slow and incomplete for all formulations they were fast 
from Eudragit RL microspheres. The combination of RS and RL polymers 
resulted in the slowed down release rates and was suitable for peroral 
administration. 
 
 Bogataj et al., (2005)73 have studied the effect of various preparation 
temperatures (10, 25, 35 400C) in solvent evaporation process on Eudragit RS 
microsphere properties (particle size and morphology, drug content and release 
kinetics and drug crystal state). At 100C particles of irregular shape were formed, 
where higher temperatures gradually improve the sphericity of microspheres. The 
results also showed that temperature has no effect on either Ketoprofen 
microencapsulation efficiency or on its crystal state. 
 
 Orlu M et al., (2006)74 have studied the design and the evaluation of colon 
specific drug delivery system containing Flurbiprofen microsponges. Microspnges 
containing Flurbiprofen (FLB) and Eudragit RS 100 were prepared by quasi- 
emulsion solvent diffusion method. Additionally FLB was entrapped into a 
commercial Microsponges® 5640 system using entrapment method. Afterwards, 
the effect of drug/polymer ratio, inner phase solvent amount, stirring time and 
speed and stirrer type on the physical characteristics of microsponges were 
investigated. The thermal behavior, surface morphology, particle size and pore 
structure of microsponges were examined. The colon specific formulations were 
prepared by compression coating and also pore plugging of microsponges with 
pectin: Hydroxypropylmethyl Cellulose (HPMC) mixture followed by tableting. It 
was concluded that both the microsponges prepared by quasi-emulsion solvent 
diffusion method and Microsponge® 5640 can be used successfully in the 
systems designed for colon specific drug delivery. 
 
 Yan Gao et al., (2006)75 have prepared microspheres of Roxithromycin with 
Eudragit RS 100 ad silica by the emulsion solvent diffusion method to mask the 
bitter taste of the antibiotic. The effect of different polymers and drug/polymer 
ratios on the taste masking and the characteristics of the microspheres were 
investigated. It was found that Eudragit RS 100 was the best for masking the 
unpleasant taste of Roxithromycin among the six kinds of polymers investigated. 
The influence of other formulation factors, i.e. dichloromethane-acetone ratios 
and silica-polymer ratios on the properties of the microspheres were also 
examined. In conclusion, the results of the present study will be helpful for the 
preparation of oral forms of Roxithromycin with an acceptable taste. 
 
 Chen G et al., (2005)76 have worked on the culturing of skin fibroblast in a thin 
PLGA-collagen hybrid mesh. The hybrid mesh was constructed by forming web- 
like collagen microsponges in the openings of a PLGA knitted mesh. The results 
indicate that the web-like collagen microsponges formed in the openings of the 
PLGA Knitted mesh increase the efficiency of cell seeding, improved cell 
distribution, and therefore facilitated rapid formation of dermal tissue having a 
uniform thickness. PLGA collagen microsponges are useful in the skin tissue 
engineering. 
 
 Cevher E et al., (2006)77 have worked on the design and evaluation of colon 
specific drug delivery system containing Flurbiprofen microsponges. Flurbiprofen 
(FLB) microsponges were prepared by quasi emulsion solvent diffusion 
techniques using Eudragit RS 100 as polymer. The effect of drug/polymer ratio, 
inner phase volume, stirring time and rate, on physical properties of the 
microsponges were determined. The results show that the microsponges were of 
spherical shape with spherical and cylindrical hole like pores. The plastic 
properties of microsponges allow direct compression of the microsponges to 
obtain mechanically strong tablets than the physical mixture of drug and polymer. 
The I vitro release profile shows that the drug release from the microsponges was 
faster than compared to the rigid micro particles due to more porous internal 
structure of microsponges. 
 Jelvehgari M et al., (2007)78 have worked on the preparation, characterization 
and release studies of Benzyle Peroxide microsponges. The effect of 
drug/polymer ratio on topography, particle size and distribution and porosity were 
analyzed. According to the results, the topographical study shows that the micro 
particles obtained were spherical and contain interconnected pores (appearing like 
a sponge); with increase in drug/polymer concentration the mean particle size of 
the sponges decreased.. The drug release studies were done by formulating BPO 
microsponges as a cream. The release shows that as the drug/polymer ratio 
increases the release of drug from BPO microsponge cream was reduces because 
of the decreased internal porosity of the microsponges with increase in 
drug/polymer. 
 
 
 Nokhodchi A et al., (2007)79 have worked on the factors affecting the 
morphology of BPO microsponges. BPO microsponges were prepared using an 
emulsion solvent diffusion method by adding an organic internal phase containing 
BPO, ethyl cellulose and dichloromethane (DCM) into a stirred aqueous phase 
containing polyvinyl alcohol (PVA) with stirring for about 8hrs until complete 
diffusion of DCM. The results shows that the microsponges obtained by this 
techniques were predominantly of spherical shape and contain orifices with 
sponge like appearance. The effect of drug/polymer ratios on morphology, 
particle size and size distribution were determined; with increase in drug/polymer 
concentration the porosity and the mean particle size size of the sponges 
decreased. The prepared microsponges were formulated as lotions and the drug 
release was performed. The data show that an increase in drug/polymer ratio 
resulted in a reduction in the release rate of drug from BPO microsponge lotions, 
due to decreased internal porosity of the microsponges. 
 
 Wester RC et al., (1991)80 have revealed that the controlled release of BPO from 
a porous microsphere polymeric system can reduce topical irritancy. The 
controlled release of BPO to skin can alter the dose relation that exists between 
efficacy and skin irritation. Corresponding studies showed reduced skin irritation 
in cumulative irritancy studies in rabbits and human beings, where as in vivo 
human antimicrobial efficacy studies showed that application of the formulations 
containing entrapped BPO significantly reduced counts of Propioni bacterium 
acnes (p less than 0.001) and aerobic bacteria (p less than 0.001) and the free fatty 
acid/triglyceride ratio in skin lipids. These findings supports the hypothesis that, 
at least for this drug, controlled topical delivery can enhance safety without 
sacrificing efficacy. 
 
 Netal Amrutiya et al., (2009)81 have worked on development of microsponges 
for topical delivery of Mupirocin and they prepared microsponges containing 
Mupirocin by an emulsion solvent diffusion method. The effect of formulation 
and the process variables such as internal phase volume and stirring speed on the 
physical characteristics of microsponges were examined on optimized 
drug/polymer ratio 32 factorial design. The optimized microsponges were 
incorporated into an emulgel base. In vitro drug releases, ex vivo drug deposition, 
and in vivo antibacterial activity of mupirocin-loaded formulations were studied. 
And they have concluded that, the formulations showed enhanced retention of 
drug in skin, indicating better potential of delivery system as compared with 
marketed mupirocin ointment and conventional Mupirocin emulgel. 
 
 Ferhan Sevgi et al., (2009)82 have worked on formulation, in vitro release and in 
situ studies in rats of mefenamic acid micro particles and they prepared 
mefenamic acid loaded Chitosan and alginate beads by Ionotropic gelation 
process and microsponges containing mefenamic acid and Eudragit RS 100 by 
quasi emulsion solvent diffusion method and they investigated the in vitro 
characteristics of mefenamic acid micro particles as well as their effects on DNA 
damage. 
 
 Vikas Jain et al., (2009)83 have worked on development and characterization of 
Eudragit RS 100 loaded microsponges and its colonic delivery using natural 
Polysaccharides. Paracetamol loaded Eudragit based microsponges were prepared 
using quasi-emulsion solvent diffusion method. The compatibility of the drug 
with various formulation components was established. Process parameters were 
analyzed in order to optimize the formulation. Shape and surface morphology of 
the microsponges were examined using scanning electron microscopy. The colon 
specific formulations were prepared by compression coating of microsponges 
with pectin: hydroxymethylcelllulose (HPMC) mixture followed by tableting. The 
in vitro dissolution studies were done on all formulations and the results were 
evaluated kinetically and statically. And concluded that the prepared 
microsponges exhibited characteristics of an ideal delivery system for colon 
targeting. The unique compressibility of microsponges offers a new alternative for 
producing mechanically strong tablets. Further colon specific tablets based on 
microsponges could prevent effective local action ad microsponges may 
selectively be taken up by the macrophages present in colon. 
 
 Yan yang et al., (2009)83 have worked on development of highly porous large 
PLGA micro particles for pulmonary drug delivery. They introduced a new 
process of making highly porous large polymeric micro particles for local drug 
delivery to the lungs by inhalation. Poly (lactic-co-glycolic acid) (PLGA) micro 
particles (average diameter, 10-20mm) were prepared by the double-emulsion 
method, in which PLGA was dissolved in dichloromethane. Freshly prepared 
Ammonium Bicarbonate solution (1% or 1.5%) was added to the polymer 
solution, and the mixture was sonicated in ice bath. The sonicated mixture was 
added to 1% polyvinyl alcohol (PVA) solution while it was being homogenized at 
a rate ot 2000-6000 rpm for 1min, then poured into water, and stirred overnight at 
room temperature to remove dichloromethane. The particles were collected by 
centrifugation at 4000 rpm for 5min, washed 3 times with distilled water, and 
filtered through wet-sieve and dried. 
 Vikas jain et al,(2010)84 Have prepared eudragit based microsponge with 
potential for colonic delivery they have choosan dicyclomine as a model drug 
.invitro dissolution study showed that increased drug : polymer resulted in 
reduction from the microsponge drug release was biphasic with an initial effect 
with 16-30% of drug was released in the first 1 hr.cumulative release for the 
microsponges over 8 hrs ranged from 59-86%. 
 
 Katarzyna winnicka et al,(2012)84 Investigated the inflence of PAMAM NH2 of 
PAMAM-OH dendrimers generation 2 and 3 generation on the soulbility and 
antifungal activity of ketoconazole and to design and evaluate ketoconazole 
hydrogel of PAMAM dendrimers.the antifungal activity of designed ketoconazole 
with PAMAM NH2 dendrimers measured by the plate diffusion method was 
definitely higher than the pure ketoconazole hydrogel and also as compared to 
commercially available product. 
5. DRUG PROFILE 
 
Chemical structure of Sertaconazole85 
 
 
 
Description: Sertaconazole is a antifungal medication of the imidazole class. It 
is avoidable as a cream to treat skin infection such as athlete’s foot. 
Chemical formula: C20H15Cl3N2OS 
IUPAC Name: 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4- 
dichlorophenyl)ethyl}-1H-imidazole 
 
Therapeutic efficacy 
In randomized, double-blind, multicentre trials of 3–6 weeks' duration (n=127- 
383), a significantly greater number of patients with tinea of the glabrous skin and tinea 
pedis receiving a topical 2% sertaconazole cream once or twice daily achieved a 
successful mycological cure copmared with recipients of a placebo cream. Sertaconazole, 
a topical azole antifungal agent, exhibits a dual antifungal mechanism of action, 
antibacterial activity, and antiinflammatory properties and demonstrates a broad spectrum 
of activities against numerous fungal pathogens. Topical Sertaconazole is efficacious and 
safe in the treatment of cutaneous dermatophytosis, tinea versicolor (pityriasis 
versicolor), cutaneous candidiasis, intertrigo and seborric dermatitis. Pharma-kinetic 
properties demonstrates an epidermal reservoir effect post treatment. Sertaconazole has 
proven to be both safe and well tolerated, based on available data worldwide. 
Sertaconazole 2% cream is the most recently introduced topical azole antifungal 
agent in the united states indicated for treatment of tinea pedis86,87. 
Mechanism of action: 
 
Similar to other azole antifungal agents, Sertaconazole inhibits lanosterol 14- 
alpha demethylis resulting in subsequent reduction in synthesis of ergosterol, the primary 
sterol contributing to fungal cell membrane function and stability88, 89. The decreased 
availability or ergosterol coupled with intracellular accumulation of 14-alpha- 
methylesterols leads to increased membrane rigidity, alteration in membrane permeability 
changes in important membrane bound enzymes growth inhibition and ultimately death 
of fungal cells90,91. In addition it has been reported that Sertaconazole induces direct 
damage to memmbranes of susceptible organism through binding to non sterol lipids 
resulting in impaired mmembrane regulatory function, leakage or intracellular contents 
such as adenosine triphosphate and rapid cell death. Sertaconazole also has been shown 
to exhibit anti-inflammatory activity and anti-bacterial activity against some 
staphylococci and streptococci92. 
Anti-inflammatory property: 
 
The anti-inflammatory properties of several antifungal agents including 
miconazole, fluconazole, Sertaconazole, terconazole, ketoconazole and ciclopirox where 
studies in multiple invivo and inviitro preclinical models of cutaneous inflammation and 
pruritus with Sertaconazole exhibiting the greatest ability to suppress cytokine release 
from phytohemagglutinin-stemulated human peripheral blood lymphocytes93. It has also 
been reported that Sertaconazole was superior to other tested azole antifungal agents 
including ketoconazole in reducing irritant dermatitis in an year edema model and that it 
reduced scratching response in a murin model of pruritus comparable to hydrocortisone94. 
The anti- inflammatory properties of antifungal agents such as Sertaconazole are believed 
to be important in symptom reduction especially early in the course of treatment and may 
obviate the need for application of other topical antipruritic agents. 
Pharmacokinetic properties: 
 
The lipophilicity of Sertaconazole related to its synthesis with a lipophilic 
benzothiophene ether is believed to Contribute to enhancement of epidermal penetration 
after topical application, with negligible systemic absorption noted on plasma analysis95. 
A cutaneous reservoir affect has been noted, with 72% of the applied dose of 
Sertaconazole present at 24Hrs after application and with a cutaneous retention time test 
demonstrating the superior antifungal effect of Sertaconazole at 12, 24, and 48Hrs after 
application compared with that of bifonazole. Although approved product labelling for 
Sertaconazole Nitrate 2% cream in the United States indicates an application frequency 
of twice daily, the persistence of antifungal activity after application and the cutaneous 
reservoir affect explain why this agent has been shown to be effective after application 
once daily. 
Spectrum of Activity 
 
Sertaconazole has been shown to be active against dermatophytes, including T 
rubrum, T mentagrophytes, and E floccosum; yeasts, including C albicans, C glabrata, C 
krusei, Candidaparapsilosis, C trophicalis, and M furfur; and some gram positive 
bacteria, including staphylococcal and streptococcal organisms. The antifungal activities 
of Sertaconazole against fungal isolates known to cause superficial fungal infection has 
been shown to be comparable or superior to that of other topical antifungal agents, 
including bifonazole and terpinafine96,97. 
Eudragit RS10098 
 
Chemical name:  poly (ethyl acrylate-co-methyl methacrylate co-trimethylamino 
ethyl methacrylatechloride) 
Chemical structure: 
 
 
Molecular weight: 32000g/mol 
 
Description: Colourless, clear to cloudy granules with a faint amine like odor . 
 
Solubility:  1g of the substances dissolves in aqueous methanol ethanol and 
isopropyl alcohol as well as in acetone ethyl acetate and 
methylene chloride to give clear to cloudy solution the substances 
are practically insoluble in petroleum ether 1N sodium hydroxide 
and water. 
Product form: Granules 
 
Targeted drug release area: Time controlled release, pH independent. 
 
Drug Substance/Residue on evaporation : 1g of the polymer is dried in an oven for 5hr 
in vaccum at 80oC. Not less than 97%. 
Loss on drying: Max.3.0%according to “dry substance/residue on evaporation. 
Storage: Protect from light temperature and moisture. Storage at any 
temperature between 80C and 250C fulfils this require ment. 
Stability : The product is required minimum stability datas are given on their 
labels and batch related analysis for certificates. 
POLYVINYL ALCOHOL (PVA)98 
 
Chemical Name: Ethanol Homopolymer 
Chemical Structure: 
 
 
where R = H or COCH3 
 
Description: Odorless, translucent, white or cream-colored granular powder. 
 
Solubility: Soluble in water, sparingly soluble in ethanol. 
 
Uses: Coating, binder, sealing agent and surface-finishing agent. 
 
TRIETHYL CITRATE98 
 
Chemical Name: 1,2,3-Triethyl 2-hydroxypropane-1,2,3-trycarboxylate 
 
Chemical Structure: 
 
 
Molecular Weight: 276.283 g/mol. 
 
Appearance: Oily Liquid. 
Uses:  Tryethyl Citrate is used in pharmaceutical coatings and plastics. It is also used 
as a plasticizer for polyvinylchloride and similar plastics. 
 
 
 
 
GLYCEROL98 
 
 
 
 
 
Description: Glycerol is a clear, colorless, odorless, viscous, hydroscopic liquid. 
It has a sweet taste. 
 
Molecular Formula: C6H8O3 
Molecular Weight: 92.09 
Melting Point: 17.8°C 
Boiling Point: 290°C 
Hydroscopicity: Hydroscopic 
Density: 1.2636 g/cm3 at 20oC 
Solubility: Slightly soluble in acetone, practically insoluble in benzene, 
chloroform, oil, soluble in ethanol (95%), methanol, and water. 
Incompatibilities: with strong oxidizing agent. 
 
Functional Category: Antimicrobial preservative, emollient, humectants. 
6. MATERIALS AND METHODS 
Table: 3 
List of Chemicals 
 
Sl. No: Material Supplier 
1 Sertaconazole Royal Pharm, Hanghou (China) 
2 Eudragit RS100 Degussa India Pvt. Ltd, Mumbai 
3 Triethyl Citrate Sigma Aldrich Pvt. Ltd, Mumbai 
4 Poly Vinyl Alcohol Loba Chemical Pvt. Ltd, Mumbai 
5 Ethyl Alcohol Changshu Yangyuan Chemical, China. 
6 Carbopol 940 Yaro Chem Pvt. Ltd, Mumbai 
7 Triethanolamine Nice Chemicals, Cochin 
8 Methyl Paraben Nice Chemicals, Cochin 
9 Propyl Paraben Nice Chemicals, Cochin 
10 Sodium Hydroxide Rankem, Gurgaon 
11 Potassium Hrydrogen Phosphate Nice Chemicals, Cochin 
Table: 4 
List of Equipment‟s & Instruments used 
 
Sl. No: Name Manufacturer 
1 Homogenizer – Stirrer Remi Motors, Mumbai 
2 Magnetic – Stirrer Remi Motors, Mumbai 
3 Ultra Sonicator Serve well instrument Pvt.Ltd,Banglore 
4 Hot Air Oven Techno Scientific Products 
5 Electronic Weighing Balance BEL Engineering 
6 UV/Visible Spectrophotometer Shimanduz, Japan UV-1700 
7 Franz Diffusion Cell LabECX 
8 Digital pH Meter Labtronics Model LT-10 
9 Melting Point Apparatus Labtronics 
10 FT-IR Spectrometer Shimanduz, Japan IR Affinity – 1 
6. METHODS 
6.1 PREPARATION OF CALIBRATION CURVE OF SERTACONAZOLE IN 
PHOSPHATE BUFFER pH4 
6.1.1 Preparation of standard stock solution of sertaconazole in phosphate buffer 
pH4 
6.1.2 Preparation of calibration curve of sertaconazole. 
6.2 PREFORMULATION STUDIES. 
6.2.1 Determination of melting point. 
6.2.2 Determination of wave length. 
6.2.3 Determination of solubility. 
6.2.4 Determination of pH. 
 
 
6.3 PREPARATION OF MICROSPONGES OF SERTACONAZOLE . 
6.3.1 Preparation of microsponge. 
6.3.2 Incorparation of sertaconazole microsponges in to gel formulation. 
 
 
6.4 EVALUATION OF MICROSPONGES OF SERTACONAZOLE 
6.4.1 Drug-Excipient Compatibility Studies. 
6.4.2 Determination Percentage Yield. 
6.4.3 Drug Loading And Drug Entrapment 
6.4.4 Particle Size Analysis. 
6.4.5 Morphology Study Using Scanning Electrone Microscope. 
6.4.6 In Vitro Dissolution Studies 
 
 
6.5 EVALUATION OF SERTACONAZOLE MICROSPONGE GEL 
6.5.1 Visual Inspection. 
6.5.2 pH Measurement. 
6.5.3 Spreadability Studies. 
6.5.4 Viscosity Measurement. 
6.5.5 In Vitro Drug Release. 
6.1 PREPARATION OF CALIBRATION CURVE OF SERTACONAZOLE IN 
PHOSPHATE BUFFER pH 4.0 
6.1.1 Scanningof standard stock solution of sertaconazole in phosphate bufferpH 4.0 
The solution containing 30µg/ mL of sertaconazole in phosphate buffer pH 4.0 
was prepared and scanned over the range of 200-400 nm against phosphate buffer 
pH 4.0 as a blank using Shimadzu UV/Visible double beam spectrophotometer. 
The solution exhibited UV maxima at 260 nm 99. 
 
6.1.2 Preparation of standard calibration curve in phosphate buffer pH 4.0 
Accurately weighed 10 mg of sertaconazole was transferred to a 100 mL 
volumetric flask and dissolved in sufficient quantity of phosphate buffer pH 4.0. 
The volume was adjusted to the mark with phosphate buffer pH 4.0 to prepared 
stock solution of 100 μg/ mL. From the stock solution aliquots of working 
solution of sertaconazole were transferred in to a series of 10 mL volumetric flask 
and made volume up to mark with phosphate buffer pH 4.0. The absorbance of 
resulting solution was measured at 260 nm against blank solution prepared 
similarly without drug using Shimadzu UV/Visible double beam 
spectrophotometer. The standard curve is generated using Microsoft excel 2007 
by plotting concentration verses absorbance. The experiment was performed in 
triplicate and average values with standard deviation were reported. The method 
obeys Beer-Lambert’s law in concentration range of 5-30 μg/ mL. 
 
6.2 PREFORMULATION STUDIES99 
Preformulation test is the first step in rational developments of dosage forms of a 
drug substance. Pre formulation study is the process of optimizing the delivery of 
drug through determination of physicochemical properties of the new compound 
that could affect drug performance and development of an efficacious, stable and 
safe dosage form. It gives the information needed to define the nature of the drug 
substance and provide a framework for the drug combination with pharmaceutical 
excipients in the dosage form. Hence, preformulation studies were performed on 
the obtained sample of drug for identification and compatibility studies. The 
following preformulaton studies were performed for sertaconazole. 
6.2.1 Determination of Melting Point. 
Melting point of drug was determinted by capillary tube method, by taking small 
amount of drug in a capillary tube, in which the other end is closed. The capillary 
tube was placed in a melting point apparatus and the temperature at which the 
drug melt was recorded. The procedure was repeated thrice to get average value. 
6.2.2 Determination of Solubility 
Solubility is one of the important consideration in formulation. The solubility test 
in various solvents such as distilled water, methanol, ether, alcohol, methelene 
chloride were estimated. 
6.2.3 Determination Of pH 
The determination is carried out at a temperature of 250C ± 2, unless otherwise 
specified in the monograph. The pH value of the solution is determined 
potentiometry. 
 
6.3 PREPARATION OF MICROSPONGES OF SERTACONAZOLE100. 
6.3.1 Preparation of Microsponges 
Microsponges were prepared by the quasi emulsification solvent diffusion 
method. 
Inner phase: It is prepared by dissolving the Eudragit RS100 in ethanol. The drug was 
added to the solution and dissolved under ultra-sonication at 35oC for 
15mins. 
Outer phase: Dissolving PVA in distilled water and the process was carried out at room 
temperature, then the inner phase was poured into outer phase ta room 
temperature. After emulsification, the mixture was continuously stirred at 
500rpm for 2Hrs. After the formation of Microsponges, the mixture is 
filtered to separate the Microsponges. The product was washed and dried 
in oven at 40oC. For the evaluation of the Drug: Polymer ratio on the 
physical characteristics of Microsponges. Seven different weighing ratio 
of drug to Eudragit RS100 are 1:1, 1:2, 1:3, 1:4, 1:5, 1:6 and 1:7. 
 
 
Table: 5 
Composition of Sertaconazole Microsponges Formulation 
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F1 1:1 0.2 0.2 RS100 10 1 200 0.4 500 2 
F2 1:2 0.2 0.4 RS100 10 1 200 0.4 500 2 
F3 1:3 0.2 0.6 RS100 10 1 200 0.4 500 2 
F4 1:4 0.2 0.8 RS100 10 1 200 0.4 500 2 
F5 1:5 0.2 1.0 RS100 10 1 200 0.4 500 2 
F6 1:6 0.2 1.2 RS100 10 1 200 0.4 500 2 
F7 1:7 0.2 1.4 RS100 10 1 200 0.4 500 2 
---- 
 
Table: 6 
Optimum values for Microsponges 
 
Drug Polymer ratio 1:1, 1:2, 1:3 etc. 
Amount of drug 2gm 
PVA 30 – 70mg 
Inner phase solvent Ethyl Alcohol 
Amount of inner phase solvent 10ml 
Amount of water in outer phase 200ml 
Temperature of inner phase 37oC 
Stirring rate 500rpm 
Stirring time 60mins 
6.3.2 Incorporation of Sertaconazole loaded Microsponges into gel formulation 
 
Sertaconazole Microsponge gel was prepared by using following formula given in the 
below table. A clear dispersion of carbopol was prepared in water using moderate 
agitation. 
 A clear dispersion of carbopol (35mg) is prepared in water (q.s) using moderate 
agitation. 
 Triethanolamine (1-2 drops) is used to neutralize the formulation and 
subsequently preservatives Methyl Paraben (3mg) and Propyl Paraben (1mg) was 
added to resist the microbial growth. 
 And then volume was maintained with water. Gel prepared were degassed with 
ultra sonication. 
Table: 7 
Table revealing the master formula for gel formulation 
 
S. No. Ingredient Quantity (mg/ml) 
1 Carbopol 940 35 
2 Triethanolamine 2 
3 Methyl Paraben 3 
4 Propyl Paraben 1 
5 Distilled Water q.s 
 
 
6.4 EVALUATION OF MICROSPONGES OF SERTACONAZOLE101 
 
6.4.1 Drug Excipient Compatibility Studies Using FT-IR 
 
The compatibility study of sertaconazole with other excipients was done by using 
Fourier transform infrared spectroscopy (FT-IR). FT-IR spectra of pure drug and mixture 
of drug and other excipients were measured using FT-IR instrument using KBr method. 
The samples to be tested were mixed with solid potassium bromide (KBr). The mixture 
was then pressed into a very thin pellet. The pellets were placed in the holder directly in 
the IR laser beam. Spectra were recorded using Shimadzu FTIR- 8400s loaded with IR 
solution version 1.2 software. The FT-IR spectrum of physical mixture was compared 
with the standard FT-IR spectrum of the pure drug for any major interaction. Each 
spectrum was recorded in the frequency range of 3800-600cm-1 IR spectra of 
sertaconazole ,Eudragit RS 100, physical mixture of both and microsponge formulation 
of sertaconazole and Eudragit RS 100 were done using FTIR spectrometry. 
 
6.4.2 Determination of Percentage Yield 
 
The prepared microsponges of all batches were accurately weighed. The 
measured weight of prepared microsponges was divided by the total amount of all the 
excipients and drug used in the preparation of the microsponges, which give the total 
percentage yield of floating microsponges. It was calculated by following equation, 
 
 
% Yield = 
 
Practicle yield 
Therotical yield( excipient+sdrug) 
 
x 100 
 
6.4.3 Drug Loading and Drug Entrapment 
 
Microsponges equivalent to 100mg of the drug were taken for evaluation. The amount 
of drug entrapped was estimated by dissolving with 100ml 7.4 phosphate buffer solution with 
the aid of sonication. The solution was filtered and the absorbance was measured after suitable 
dilution spectrophotometrically (UV 1700, Shimadzu, japan) at 260 nm against appropriate 
blank. The amount of drug loaded and entrapped in the microsponges was calculated by the 
following formulas: 
 
 
% Drug Loading = 
 
Weight of the drug loaded in the microsponges (DC) 
Total weight of the microsponges 
 
x 100 
 
 
% Encapsulation 
efficiency = 
Amount of drug actually present (DC) 
Theoretical drug load expected 
 
x 100 
 
(DC = Actual Drug Content) 
6.4.4. Particle size analysis 
 
Determination of average particle size of sertaconazole microsponge was 
determined by an optical microscope using caliberation ocular and stage micrometer 
under regular polarized light. A minute quantity of microsponge spread on clean glass 
slide and the average particle size was calculated by measuring 100 particle of each 
batch. 
6.4.5 Morphology Study Using Scanning Electrone Microscope 
The internal and external morphology and surface topography can be studied by 
scanning electron microscopy (SEM). Prepared microsponges can be coated with gold– 
palladium under an argon atmosphere at room temperature and then SEM images of 
microsponges were recorded at the required magnification. SEM of a fractured 
microsponge particle can also be taken to illustrate its ultra structure. 
 
6.4.6 In Vitro Dissolution Studies 
 
Dissolution profile of microsponges can be studied by use of dissolution 
apparatus USP XXIII with a modified basket consisted of 5μm stainless steel mesh. The 
speed of the rotation is 150 rpm. The dissolution medium is selected while considering 
solubility of actives to ensure sink conditions. Samples from the dissolution medium can 
be analyzed by suitable analytical methods at various intravels. 
6.5 EVALUATION OF SERTACONAZOLE MICROSPONGE GEL102 
6.5.1Visual Inspection 
The organoleptic properties such as color, texture, consistency, homogeneity and 
physical appearance of gel containing microsponges were checked by visual observation. 
6.5.2 pH Measurement 
 
Diverse gel formulation pH was recorded using digital pH meter. 5g gel was 
dispersed in 45ml distilled water at 270c and solution pH was measured. 
6.5.3 Spreadability Studies 
 
Spreadability of sertaconazole microsponge gel was measured in terms of 
diameter of gel circle produced when placed between two glass plates of definite weight. 
A weighed quantity 0.5 gm gel was placed within a circle of 1cm diameter premarked on 
a glass plate over which a second glass plate was placed. A weight of 500 gm was 
allowed to rest on the upper glass plate for 5 min. The increase in the diameter due to 
spreading of the gels was noted.(diameter of the spread circle – initial diameter). 
 
6.5.4 Viscosity Measurement 
 
The viscosity of gel formulation was determined. The viscosity was determined 
using a Brookfield digital viscometer (DV-E model). The sample holder taken for the 
viscosity measurement was filled with the samples and then inserted into a flow jacket 
mounted on the viscometer. The samples adaptor (spindle), rotated at an optimum speed 
was used to measure the viscosity of the preparation. 
 
6.5.5 Drug content. 
One gram of microsponges loaded gel was accurately weighed and dissolved in 
phosphate buffer pH 4.0 filterd and volume was made up to 100ml with buffer solution. 
The drug content was determined by diluting the resulting solution for 10 times with 
phosphate buffer and measuring the absorbance at 260nm using UV spectrophotometer. 
 
6.5.6 In-Vitro Drug Release 
 
In-vitro permeation studies using cellophane membrane 
The in-vitro release of microsponges containing Sertaconazole from the gel formulation 
was studied through cellophane membrane using modified apparatus. The dissolution medium 
used was freashly prepared phosphate buffer pH 4.0. Cellophane membrane previously soaked 
overnight in the dissolution medium, was tied to one end of a specifically designed glass 
cylinder (open at both end). 100 mg equivalent gel formulation of sertaconazole microsponges 
was kept in donor compartment. The cylinder was attached to stand and suspended in 200ml of 
dissolution medium maintained at 37±1oC. The membrane just touching the receptor medium 
surfaces. The dissolution medium was stirred at 100rpm speed using Teflon coated magnetic 
bead. Aliquots, each of 2ml volume were withdrawn periodically at predetermined time interval 
of 30, 60, 120, 180, 240,300, 360, 420,480, 540, 600min and replaced by an equal volume of 
the receptor medium. The aliquots were suitably diluted with the receptor medium and analysed 
by UV-Visible spectrometer at 260nm using phthalate buffer as blank. 
Kinetic modelling of in- vitro drug release. 
The data obtained from in vitro release studies of best two formulations were 
fitted to 
various models such as zero order, first order, Higuchi and Korsmeyer Peppas to obtain 
the 
kinetic modeling of drug release. 
To study the release kinetics the data obtained from in-vitro drug release studies 
were plotted in various kinetic models. 
1. Zero order rate kinetics: %Cum.Drug Release Vs Time 
2. First order rate kinetics: Log cum. % of drug remaining vs time. 
3. Higuchi model: Cum. percentage of drug released vs square root of time. 
4. Korsmeyer Peppas model: Log cumulative % of drug release vs log time. 
 
 
The plots were drawn using graph pad prism version 5 and the regression 
equations were obtained for each plot. The correlation coefficient value (r2) of the plot 
was obtained. The model with the highest correlation coefficient value (r2approches 
unity) was chosen as the best fit kinetic model. 
 
1. Zero order kinetics 
A zero order release can be predicted by using the equation: 
Qt = Q0 – K0t 
Where, 
Q0 = initial amount of drug present in solution (most cases Q0=0) 
Qt = the amount of drug release at time t. 
K0 = the zero order release rate constant. 
A graph of cumulative percentage of drug release vs time yields a straight line 
with a slope equals to K0. 
 
2. First order kinetics 
The first kinetics describes the release from a system where the release rate is 
concentration dependent. It can be described by the following equation: 
ln Q = ln Q0 –Kt1 Where, K1 = first order release constant. 
 
3. Higuchi model kinetic 
The drug release can be predicted by the following equation: 
Q = Kt
1/2 
Where, K is Higuchi dissolution constant. 
t is the time in hrs 
The model predicts that the drug release from the dosage form is directly 
proportional to the square root of time. 
 
4. KorsmeyerPeppas model 
To evaluate drug release mechanism of drug, the in-vitro release data was plotted 
in Korsmeyer equation as log cumulative percentage of drug release vs log time 
and exponent n was calculated through slope of the straight line. 
Korsmeyer equation as follows: 
Mt/M = Ktn 
Where, 
Mt/Mα the fractional solute release 
t = the release time 
K = the kinetic constant 
n is an exponent which indicates the mechanism of drug release. In the present 
study the limits considered were n= 0.45 indicates a classical Fickian diffusion 
controlled release and n=0.89 indicates a case II relaxation release transport; 
nonfickian, zero order release value of n between 0.45 and 0.89 can be regarded 
as an indicator of both phenomena (drug diffusion in the hydrated matrix and the 
polymer relaxation) commonly called anomalous transport. After the value 
reaches 0.89 and above the release can be characterized by case II and super case 
II transport, which means the drug release rate does not change over time and the 
release is characterized by zero order. 
 
 
 
 
Values of „n‟ Mechanism 
0.5 Fickian diffusion (higuchi matrix) 
0.5< n˂1.0 Anamolous transpot 
1 Case-II Transport(zero order) 
n>1 Super case-II transport 
7. RESULT 
 
 
Analytical method 
Figure: 7.1 
Determination Of λ max of Sertaconazole in pH 4.0 Phosphate Buffer Solution 
 
 
 
 
RESULT 
 
UV spectra of sertaconazole possess a common λmax at 260nm. This λmax is used for 
further study. 
Table:8 
Calibration curve of sertaconazole at pH 4.0 buffer solution 
 
S.No. Concentration Absorbance at 260 nm 
1 5 0.154 
2 10 0.287 
3 15 0.396 
4 20 0.531 
5 25 0.650 
6 30 0.782 
 
Figure: 7.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Result: 
The standard curve of sertaconazole was prepared in pH.4.0 phosphate buffer, the r2 
value was found to be 0.9986, which shows a linearity of absorbance between 15- 
35μg/ml. 
0.9 y = 0.025x + 0.016 
R² = 0.998 
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PREFORMULATION STUDIES 
 
Table: 9 Preformulation studies 
 
 
The following preformulation studies were performed for sertaconazole. 
 
 
Melting point 146± 1.23°C 
Solubility Practically insoluble in water, soluble in methanol, 
sparingly soluble in alcohol and methelene chloride. 
pH 6 
λmax 260nm 
Colour White or almost white powder 
 
 
 
 
 
RESULT 
The preformulation studies for the drug was conducted. The λmax of sertaconazole was 
found at 260nm. By determining the organoleptic poperties, it was observed that the drug 
was found to be white colour, and odourless. Solubility study showed that sertaconazole is 
practically insoluble in water, soluble in methanol, sparingly soluble in alcohol and 
methelene chloride. The melting point was found at 146°C. 
 Drug-Excipient Compatibility Studies 
Preformulation studies were carried out to study the compatibility of pure drug 
Sertaconazole with the other excipient. The individual IR spectra of the pure drug and 
other excipient as well as the combination spectra of the drug and polymer are shown in 
the Figure: 11 which indicates no interaction between sertaconazole and other excipient 
when compared with infrared spectrum of pure drug as all functional group frequencies 
were present. 
 
 
 
Figure: 7.3 FTIR of Eudragit RS 100 
 
 
 Figure: 7.4 FTIR spectra of Sertaconazole 
 
 
 
 
Figure : 7.5 FTIR spectra of drug+ polymer 
 
 Preparation of microsponges 
Free flowing powder particles of Sertaconazole were obtained by quasi-emulsion solvent 
diffusion method with Eudragit RS 100 in ethyl alcohol. The quasi-emulsion solvent 
diffusion method used for the preparation of the microsponges was simple reproducible, 
and rapid. Surface morphology by SEM observed in fig 12. revealed the micro porous 
nature of microsponges. 
 
 
 
Figure: 7.6 Different formulations of microsponges 
 
 
Evaluation of Sertaconazole microsponges 
Table 10. Average particle size of Sertaconazole microsponges 
 
 
Formulation code Average particle size(µm) (Mean± SD)n=3 
FI 23.9±1.02 
F2 27.5±1.05 
F3 29.3±1.54 
F4 31.1±1.32 
F5 33.7±1.25 
F6 34.1±1.23 
F7 37.5±1.19 
 
Figure: 7.7 Average particle size distribution graph 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULT 
Visual inspection of all batches done using optical microscope for particle size analysis 
which shows that increased particle size with increase in drug : polymer ratio 
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Table: 11 Table revealing the results of Percentage Yield, Encapsulation Efficiency 
And % Drug Content 
 
 
SL. 
NO: 
Formulation 
code 
Percentage 
yield ±SD 
Encapsulation 
efficiency ±SD 
% Drug content 
(conc*dil.factor*100) 
1 F1 60 ± 0.23 79.94 39.97 
2 F2 71.6± 0.13 86.93 57.95 
3 F3 73.7± 0.18 91.89 68.93 
4 F4 75.4± 0.016 94.28 74.42 
5 F5 77.2± 0.12 95.39 79.19 
6 F6 79 .9± 0.42 96.41 81.23 
7 F7 81.5± 0.02 98.25 85.42 
 
RESULT 
The drug content in each formulation were analysed spectrometricaly and it was observed 
that all the formulation showed satisfactory drug content values ranging from 39.97% to 
85.42 % as given in the table 11. Percentage yield of all batches of microsponges ranged 
from 60±0.23 to 81.5±0.02. Encapsulation efficiency of all 7 batches ranging from 79.9 
to 98.2. 
Figure: 7.8 Percentage yield graph 
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Figure: 7.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure: 7.10 
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Figure: 7.11 
SEM Photographs Of Sertaconazole Microsponges 
 
 
 
 
Figure: 7.12 
 
 
 
  
 
Table: 12 
Cumulative % Drug Release of Sertaconazole Microsponge In Different 
Formulations 
Time(hr) 
% Cumulative Drug Release 
F1 F2 F3 F4 F5 F6 F7 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
1 20.11 25.36 19.36 9.28 15.25 23.01 30.42 
2 22.36 28.95 21.69 20.48 22.36 28.95 44.53 
3 27.38 30.58 28.36 27.65 26.36 36.37 59.37 
4 36.11 35.23 35.28 35.36 31.25 44.36 61.97 
5 38.48 39.85 45.23 37.15 36.25 55.36 63.82 
6 44.53 46.00 48.58 44.25 40.10 58.63 73.47 
7 55.96 50.85 57.15 47.36 51.36 63.46 79.04 
8 66.05 58.48 68.25 58.30 66.80 67.54 83.86 
9 68.56 63.56 77.93 68.14 71.25 73.48 84.60 
24 70.88 74.22 76.36 81.64 82.75 89.06 92.03 
Figure: 7.13 Cumulative % Drug Release of Sertaconazole Microsponges In 
Different Formulations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULT 
The cumulative % release from the formulation was in the range of 70.88% - 92.03%. 
From the seven formulation namely F7 shows satisfactory sustained effect and a 
maximum drug release of about 92.03% in 24 hrs was seen. So this formulation is 
selected for further kinetic studies. 
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RELEASE KINETICS OF SERTACONAZOLE MICROSPONGE IN 
FORMULATION F7 
Consolidation Chart Of Kinetic Study Of F7 Formulation 
 
Table: 13 Consolidation Chart Of Kinetic Study Of F7 Formulation 
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0 0 0 0 0 0 0 0 0 0 0 
1 0.0082 0.32031 0.2883 0.6086 30.4297 1.4833 69.5703 1.8424 0 1 
2 0.012 0.46875 0.4219 0.8906 44.5313 1.6487 55.4688 1.7440 0.3010 1.4142 
3 0.016 0.625 0.5625 1.1875 59.3750 1.7736 40.6250 1.6088 0.4771 1.7320 
4 0.0167 0.65234 0.5871 1.2395 61.9727 1.7922 38.0273 1.5801 0.6020 2 
5 0.0172 0.67188 0.6047 1.2766 63.8281 1.8050 36.1719 1.5584 0.6989 2.2360 
6 0.0198 0.77344 0.6961 1.4695 73.4766 1.8661 26.5234 1.4236 0.7781 2.4494 
7 0.0213 0.83203 0.7488 1.5809 79.0430 1.8979 20.9570 1.3213 0.8450 2.6457 
8 0.0226 0.88281 0.7945 1.6773 83.8672 1.9236 16.1328 1.2077 0.9030 2.8284 
9 0.0228 0.89063 0.8016 1.6922 84.6094 1.9274 15.3906 1.1873 0.9542 3 
27 0.0248 0.96875 0.8719 1.8406 92.0313 1.9639 7.9688 0.9014 1.3802 4.8989 
Figure: 7.14 Zero order plot of f7 formulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure: 7.15 First order plot of F7 formulation 
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Figure: 7.16 Higuchi plot of F7 Formulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure: 7.17 Korsemeyer plot of F7 formulation 
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REGRESSION COEFFICIENT (R2) VALUES OF KINETIC MODEL FOR 
FORMULATION F7 
 
Table: 14 Regression Coefficient (r2) values of Kinetic model for formulation f7 
 
 
 
 
 
Formulation 
KINETIC DRUG RELEASE MECHANISM OF RELEASE 
ZERO 
ORDER 
FIRST 
ORDER 
HIGUCHI 
KORSEMEYER 
PEPPAS 
Correlation 
Coefficient 
(r2) 
Correlation 
coefficient (r2) 
Correlation 
coefficient 
(r2) 
Slope 
'n' 
value 
Correlation 
coefficient 
(r2) 
F7 0.96 0.95 0.94 0.44 0.84 
 
 
 
 
 
RESULT 
The in vitro drug release showed highest regression value for the zero order kinetics and 
release data was best fit with Higuchi model kinetics because the value of r2 was greater 
in this model. The formulation follows the diffusion controlled mechanism for drug 
release. The n value was found to be 0.44, indicating that the drug release mechanism 
was diffusion and non fickian release. 
Table: 15 
 
 
EVALUATION OF SERTACONAZOLE MICROSPONGE GEL. 
 
 
Visual inspection Clear, transparent gel, viscous in nature with smooth texture, 
good homogeneity 
Spreadability 14.2±0.81 
pH 6.5 
Viscosity 265.5 cPs 
 
Table: 16 
% Drug Content of Sertaconazole Gel Formulation 
 
 
Sl. No 
 
abs 
Conc(abs/slope) 
mg/ml 
%Drug 
content(conc*dil.factor*100) 
 
1 
0.422  
785.1 ± 0.23 
 
78.1±0.01 0.423 
0.422 
 
Table: 17 
Permeability Study Data Of Sertaconazole Gel. 
 
Time 
(hr) 
Abs Conc ADD %ADD 
%Cum.Drug. 
Diffused 
0 0 0 0 0 0 
2 0.036 1.4062 14.0625 7.0312 7.0312 
4 0.052 2.0312 20.3125 10.1562 17.1875 
6 0.074 2.8906 28.9063 14.4531 31.6406 
8 0.091 3.5546 35.5469 17.7734 49.4140 
10 0.18 7.0312 70.3125 35.1562 84.5703 
Figure: 7.18 % Cumulative Drug Diffused 
 
 
8. DISCUSSION 
 
8.1 PREFORMULATION PARAMETERS 
 
8.1.1 Anaytical Method 
 
The standard c calibration curve is generated using Microsoft Excel 2007 by 
plotting concentration verses absorbance. The experiment was performed in triplicate and 
average values with standard deviation were reported. The method obeys Beer-Lambert’s 
law in range of 5-30µg/ ml. This data was further used for the calculation. 
8.1.2 Melting Point 
 
The melting point of Sertaconazole was pragmatic in range of 145-1500C 
(Literature standard 147°C). As experimental values were in good agreement with 
standard, procured drug was supposed to be pure. 
8.1.3 Organoleptic Properties 
 
By determining the organoleptic properties, it was observed that the drug was 
found to be white colour, and odourless. Solubility study showed that Sertaconazole is 
practically insoluble in water, soluble in methanol, sparingly soluble in alcohol and 
methelene chloride. 
8.1.4 Compatibility Studies 
 
FT-IR study revealed that drug loading occurred in the microsponges as both 
polymer and drug peaks have been observed. No significant deviation in the peaks was 
observed which indicated that there is no incompatibility between drug and formulation 
component. 
8.2 Microsponges 
 
In quasi emulsion solvent diffusion method affinity between good solvent and 
drug is stronger than the affinity between good solvent and poor solvent. Drug solution in 
the good solvent formed emulsion droplets (quasi) upon pouring into the poor solvent and 
the organic phase then diffused out in to the external phase resulting in the formation of 
pores in the micron-sized particles, known as microsponges that have taken a spherical 
shape due to constant stirring. 
Free flowing spherical microsponges were obtained by quasi emulsion solvent diffusion 
method with Eudragit RS100. The method seems to be promisingfor the preparation of 
Sertaconazole microsponges. 
8.2.1 Physical appearance 
 
Microsponge particle with fairy white tincture were obtained by Quasi emulsion 
solvent diffusion method. With good flow properties than as compared with pure drug. 
8.2.2 Production Yield, Encapsulation Efficiency and % Drug Content 
 
The production yield of all batches of microsponges ranged from 37.5±0.23 to 
56.87±0.02. It reflected that higher the drug :polymer ratio higher the production yield. 
This was due to a bridged ethyl alcohol diffusion rate from concentrated solutions to 
aqueous phase at higher drug: polymer concentration which provide additional time for 
formation of droplet, thereby improving yield. 
The mean amount of drug entrapped in fabricated microsponges was found to be 
lesser than theoretical value for every drug: polymer ratio employed, in view of the fact 
that drug encapsulation efficiency did not attain 100%. This was for the reason that some 
drug gets dissolved in aqueous phase or solvent used. Encapsulation efficiency outcome 
reflects that higher the drug polymer ratios leads to superior drug loadings. Here the 
encapsulation efficiency ranging from 62.2 to 76.1. 
8.2.3 Scanning Electron Microscopy (SEM) 
 
For morphology and surface topography investigation prepared micro sponge 
were subjected to SEM analysis. The captured SEM image of microsponges is shown in 
figure; 17, 18. SEM results indicated that microsponges formed were highly pours, 
predominantly spherical and not much entire sertaconazole crystals were observed 
visually. Pores were induced by diffusion of solvent from surface of microsponges. 
8.2.4 Particle Size Analysis 
 
Visual inspection results of all batches done using optical microscope for particle 
size discovered increased particle size with increase in drug: polymer ratio. It might be 
since polymer available at higher drug: polymer ratio was in more amount thereby 
increasing polymer wall thickness which leads to larger size of microsponges. 
8.2.5 Analysis of Release Mechanism 
The drug release mechanism was analysed by fitting the release data in to various 
equation like first order, zero order, Higuchi, Korsmeyer – Peppas, and by highest r2 
value best fit model was decided. Depending upon the % cummulative drug release chart 
found that formulation F7 has the maximum release (92.03).this formulation was taken as 
further study. 
The in vitro drug release showed highest regression value for the zero order kinetics and 
release data was best fit with Higuchi model kinetics because the value of r2 was greater 
in this model. The formulation follows the diffusion controlled mechanism for drug 
release. 
The in vitro drug release data were fitted to korsemyer peppas model. The n value was 
found to be 0.44, indicating that the drug release mechanism was diffusion and non 
fickian release. 
 
8.3 Evaluation of Sertaconazole Microsponge Gel 
8.3.1 Visual Inspection 
The prepared gel formulations of sertaconazole microsponges were inspected 
visually for their colour, texture and appearance. The prepared formulation were clear, 
transparent gel, viscous in nature with smooth texture and of good homogeneity with no 
any lumps. 
 
8.3.2 pH Measurement 
The pH value of prepared formulation was found in the range of 6.5, which are supposed 
to be suitable to pass up threat of nuisance on application to skin. 
8.3.3 Spreadability Study 
The spreadability of the formulated sertaconazole gel is 14.2 .The findings of 
spreadability depicted that formulated gel get easily spread on applying small amount of 
shear. Which indicating that spreadability of drug loaded microsponge gel was good. 
 
8.3.4 Viscosity Measurements 
The viscosity of prepared microsponge gel was found to be 265.5 cPs. Which was 
measured by Brookfield viscometer, then the viscosity was found to be reliant on 
polymeric content of formulation. 
 
8.3.6 Diffusion Pattern of Sertaconazole from Gel Formulation Incorporated With 
Sertaconazole Microsponges 
Incorporation of sertaconazole in the form of microsponges in to the gel 
formulation had a significant effect on the rate of release from the microsponges. The 
microsponges with drug: polymer ratio 1:7 was selected for the further incorporation in to 
gel formulation. Incorporation of the sertaconazole microsponges into the gel formulation 
resulted in decrease rate of drug release from the microsponges when compared to the 
release from the sertaconazole microsponges alone, This may be due to the increased path 
for the drug to pass through the cellophane membrane. which means the drug first has to 
be release from the microsponges to the gel base and then from the there on to the skin 
hence the time of release was high. 
CONCLUSION 
 
 In this work an attempt was made to formulate and evaluate microsponges for 
controlled release of Sertaconazole by Quasi emulsion solvent diffusion method. 
 The ratio of drug: polymer required to produce microsponges with good 
encapsulation efficiency was found to be from F7. Below this ratio, the 
microsponges formed had low capacity encapsulation of the drug and above this 
range there was no further increase in the encapsulation efficiency. Hence it was 
concluded that F7 was optimum ratio of drug: polymer to produce good 
microsponges. 
 By the drug release studies of the formulation F7 was concluded that the release 
profile was sustained and was in controlled fashion. 
 The prepared sertaconazole microsponge formulations were evaluated for drug 
content, in vitro drug release studies and invitro release kinetics. The best 
formulation was found to be F7. The pharmacokinetic model reveals that the 
mechanism of drug release from microsponges formulation was Higuchi model. 
 The selected formulation were incorporated into carbopol 940 gel base and 
evaluated for viscosity, spredability and diffusion studies. 
 Finally we may concluded that formulation F7 was best formulation to obtain 
good microsponges and sustain release of drug. 
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